Sustained-release preparation is a hot spot in antitumor drug research, where the first task\nis to select suitable drug carriers. Research has revealed that carboxylic acid iron metalâ??organic\nframeworks (MOFs), constructed from iron (Fe) ions and terephthalic acid, are nontoxic and\nbiocompatible. Due to the breathing effect, the skeleton of this mesoporous material is flexible\nand can reversibly adapt its pore size through drug adsorption. Therefore, we chose one kind of\nFe-MOF, MIL-53(Fe), as a carrier for the anticancer drug oridonin (Ori). In this work, we report\nthe design and synthesis of MIL-53(Fe) and explore its ability as a transport vehicle to deliver Ori.\nMIL-53(Fe) is characterized by scanning electron microscopy and X-ray powder diffraction. A loading\ncapacity of 56.25 wt % was measured by high performance liquid chromatography. This carrier was\nsafe and nontoxic (cell viability > 95.27%), depending on the results of 3-(4,5-dimethylthiazol-2-yl)â??\n2,5-diphenyltetrazolium bromide assays, lactate dehydrogenase assays, and Annexin V-fluoresce\nisothiocyanate/propidium iodide double-staining assays. After loading the drug, the structure of the\nMIL-53(Fe) was not destroyed, and Ori was amorphous in MIL-53(Fe). Based on an analysis of the Ori\nrelease profile, results suggest that it lasts for more than seven days in vitro. The cumulative release\nrate of Ori at the seventh day was about 82.23% and 91.75% in phosphate buffer saline solution at ..... under pH 7.2 and pH 5.5, respectively. HepG2 cells were chosen to study the cytotoxicity of\nOri@MIL-53(Fe), and the results show that the anticancer ratio of Ori@MIL-53(Fe) system reaches\n90.62%. Thus, MIL-53 can be used as a carrier for anticancer drugs and Ori@MIL-53(Fe) is a promising\nsustained-release drug delivery system for the cancer therapy.
Loading....